Shares in Tokyo-listed Nxera Pharma slid 5% at market open after Boehringer walked away from the neurological assets.

If Lobaev’s catalog reads like a roll call of overbuilt, mile-plus problem solvers, it is because these boutique .308-to-.408 ...